NCT02768363Phase 2Active not recruiting

Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)

Study sponsor: Candel Therapeutics, Inc. · CADL

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2024-11Actual

Enrollment · participants187Actual

Source updated2025-07-30Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Prostate Cancer

Treatments or interventions studied

aglatimagene besadenovecBiologicalAlso known as AdV-tk, CAN-2409
placeboBiological
valacyclovirDrug

Primary outcomes · main study measures

measure: Progression-free survival (PFS); description: Progression-free survival is defined as the time from randomization to evidence of histological disease progression or death due to prostate cancer; timeFrame: Baseline to study completion, approximately 5 years

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history